8-K/A: Organon Discloses Executive Chair Carrie Cox's Compensation
Executive Compensation Disclosure
Organon & Co. filed an amended 8-K to disclose that Executive Chair Carrie S. Cox will receive a base salary of $100,000 per month.
Summary
- Organon & Co. filed an amendment (Form 8-K/A) to its Current Report on Form 8-K, originally filed on October 27, 2025.
- The amendment specifically discloses the compensation for Carrie S. Cox in her role as Executive Chair for an interim period.
- Ms. Cox's base salary has been set at $100,000 per month, effective as of October 26, 2025.
- The compensation was determined by the Talent Committee of the Board of Directors on October 28, 2025.
- No other changes were made to the information contained in the original Form 8-K.
Sentiment
Score: 5
Explanation: Neutral. The filing is a routine disclosure of executive compensation, neither positive nor negative for the company's operational or financial performance.
Future Outlook
NA
Industry Context
NA
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Executive Chair | NA | Carrie S. Cox | 2025-10-26 | Appointment to Executive Chair, with compensation details disclosed. |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Compensation Determination | The Talent Committee of the Board of Directors determined the base salary for the Executive Chair. | 2025-10-28 | Standard corporate governance action regarding executive compensation, ensuring transparency. |
Stakeholder Impact
- Shareholders: Provides transparency regarding executive compensation, which is a component of corporate expenses and governance.
Key Dates
| Date | Description |
|---|---|
| 2025-10-26 | Effective date of Carrie S. Cox's service as Executive Chair and her compensation. |
| 2025-10-27 | Date of the original Form 8-K filing. |
| 2025-10-28 | Date the Talent Committee determined Carrie S. Cox's compensation; also the date of the earliest event reported for the 8-K/A. |
| 2025-10-30 | Date the 8-K/A report was signed. |
Recommendation
holdThe filing is a routine amendment disclosing executive compensation details. It does not contain information related to operational performance, strategic changes, or financial results that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate as there's no new material information to justify buying or selling based solely on this filing.
Keywords
Organon, OGN, SEC Filing, 8-K/A, Executive Compensation, Carrie S. Cox, Executive Chair, Corporate Governance, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.